{"id":4237,"company":{"country":"US","currency":"USD","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2023-07-12","marketCap":2.859400987625122,"name":"60 Degrees Pharmaceuticals Inc","phone":"12023275422","outstanding":12.210000038146973,"symbol":"SXTP","website":"https://60degreespharma.com/","industry":"Pharmaceuticals"},"price":1.53025,"year":2024,"month":8,"day":16,"weekday":"Friday","title":"Performance of 60 Degrees Pharmaceuticals Inc stock over the past year","date":"2024-08-16","url":"/posts/2024/08/16/SXTP","content":[{"section":"Introduction","text":"60 Degrees Pharmaceuticals Inc is a pharmaceutical company operating in the healthcare sector. In this article, we will analyze the performance of their stock over the past year, taking into consideration key financial indicators."},{"section":"Stock Price Performance","text":"Over the past year, the stock price of 60 Degrees Pharmaceuticals Inc has shown mixed results. At the beginning of the year, the stock experienced a steady upward trend, reaching its peak in the first quarter. However, since then, the stock has experienced significant fluctuations, with periods of both gains and losses."},{"section":"Revenue Growth","text":"When considering revenue growth, 60 Degrees Pharmaceuticals Inc has displayed moderate improvement over the past year. They have successfully increased their revenue by implementing strategic measures such as expanding their product line and entering new markets. This steady growth indicates positive business performance."},{"section":"Profitability","text":"In terms of profitability, 60 Degrees Pharmaceuticals Inc has faced some challenges. They experienced a decline in their profit margins due to factors such as increased production costs and intense competition in the industry. However, the company has taken steps to address these issues by implementing cost-cutting measures and investing in research and development."},{"section":"Financial Stability","text":"60 Degrees Pharmaceuticals Inc has shown a satisfactory level of financial stability over the past year. They have maintained a healthy cash flow position, allowing them to invest in growth opportunities and meet their financial obligations. Additionally, the company has a manageable level of debt, which indicates a lower risk of defaulting on their obligations."},{"section":"Market Competition","text":"One of the key challenges faced by 60 Degrees Pharmaceuticals Inc is the intense competition within the pharmaceutical industry. They operate in a highly competitive market with established players and face challenges in capturing market share. It will be crucial for the company to differentiate itself and continue innovating to remain competitive."},{"section":"Conclusion","text":"In conclusion, the performance of 60 Degrees Pharmaceuticals Inc stock over the past year has been mixed. While they experienced an initial upward trend, the stock has been subject to fluctuations. The company has shown moderate revenue growth and has taken steps to address profitability challenges. Financial stability and a manageable level of debt are positive indicators. However, the intense market competition poses a potential risk. Investors should carefully analyze these factors before making any investment decisions."}],"tags":["CrossOver21","Long","Pharmaceuticals"],"news":[{"category":"company","date":1723717440,"headline":"60 Degrees Pharmaceuticals GAAP EPS of -$4.23","id":129385919,"image":"","symbol":"SXTP","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601793128"},{"category":"company","date":1723699380,"headline":"Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Gritstone Oncology (GRTS)","id":129379005,"image":"","symbol":"SXTP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601552276"},{"category":"company","date":1723699380,"headline":"H.C. Wainwright Sticks to Their Hold Rating for 60 Degrees Pharmaceuticals, Inc. (SXTP)","id":129385921,"image":"","symbol":"SXTP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601552274"},{"category":"company","date":1723654802,"headline":"60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q2 Loss, Tops Revenue Estimates","id":129375056,"image":"https://media.zenfs.com/en/zacks.com/670d1917693293f70179651625deb88f","symbol":"SXTP","publisher":"Yahoo","summary":"60 Degrees Pharmaceuticals Inc. (SXTP) delivered earnings and revenue surprises of -6.82% and 13.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?","url":"https://finance.yahoo.com/news/60-degrees-pharmaceuticals-inc-sxtp-170002036.html"},{"category":"company","date":1723647660,"headline":"60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results","id":129354210,"image":"https://s.yimg.com/ny/api/res/1.2/0ltTP7QBKNZiLxAjpX1kVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02Mjg-/https://media.zenfs.com/en/globenewswire.com/f409c5c178ca0321d32bbd132d834ddd","symbol":"SXTP","publisher":"Yahoo","summary":"Q2 2024 net product revenues doubled year-over-year to $125 thousandSequential (quarter-over-quarter) net product revenue growth of 18.3%Gross profit increased from ($124 thousand) to $35 thousand, year-over-year WASHINGTON, Aug. 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the second quarter of 2024, ended June 3","url":"https://finance.yahoo.com/news/60-degrees-pharmaceuticals-announces-second-150100054.html"},{"category":"company","date":1723629540,"headline":"SXTP Stock Earnings: 60 Degrees Misses EPS, Misses Revenue for Q2 2024","id":129385923,"image":"","symbol":"SXTP","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3601215316"},{"category":"company","date":1723496512,"headline":"Should You Add 60 Degrees Pharmaceuticals, Inc. (SXTP) to Your Stock Portfolio Right Now?","id":129320625,"image":"https://s.yimg.com/ny/api/res/1.2/At.43jVv9Tgpc4XhgTBQ7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/9e55142f7b4ac714c97f59842ab0f46d","symbol":"SXTP","publisher":"Yahoo","summary":"We recently compiled a list of the 10 Best New Penny Stocks To Buy Now. In this article, we are going to take a look at where 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) stands against the other new penny stocks. Fears of a US recession are growing, sending stock markets down, and investors around the world are […]","url":"https://finance.yahoo.com/news/add-60-degrees-pharmaceuticals-inc-210152918.html"},{"category":"company","date":1723468320,"headline":"60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study","id":129317935,"image":"https://s.yimg.com/ny/api/res/1.2/0ltTP7QBKNZiLxAjpX1kVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02Mjg-/https://media.zenfs.com/en/globenewswire.com/f409c5c178ca0321d32bbd132d834ddd","symbol":"SXTP","publisher":"Yahoo","summary":"University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria.SJ733 will be combined with a single dose of tafenoquine in the study.The right of reference allows FDA to review 60 Degrees Pharma’s regulatory file when the agency evaluates new study protocols for the SJ733-tafenoquine Phase IIb program. WASHINGTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degre","url":"https://finance.yahoo.com/news/60-degrees-pharma-provides-university-131200159.html"},{"category":"company","date":1723467480,"headline":"Why Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?","id":129346361,"image":"","symbol":"SXTP","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597455381"},{"category":"company","date":1723461960,"headline":"H.C. Wainwright Keeps Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)","id":129313115,"image":"","symbol":"SXTP","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597343071"},{"category":"company","date":1723453920,"headline":"60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA? NDA in Support of SJ733 Phase IIb Study","id":129313117,"image":"","symbol":"SXTP","publisher":"GlobeNewswire","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=eplzt3rigx"},{"category":"company","date":1723450500,"headline":"60 Degrees granted University of Kentucky right to reference NDA for ARAKODA","id":129313119,"image":"","symbol":"SXTP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3597121036"},{"category":"company","date":1723186200,"headline":"60 Degrees Pharmaceuticals Inc trading halted, news pending","id":129276575,"image":"","symbol":"SXTP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3594816841"},{"category":"company","date":1722950760,"headline":"60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split","id":129179333,"image":"https://s.yimg.com/ny/api/res/1.2/0ltTP7QBKNZiLxAjpX1kVA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02Mjg-/https://media.zenfs.com/en/globenewswire.com/f409c5c178ca0321d32bbd132d834ddd","symbol":"SXTP","publisher":"Yahoo","summary":"WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split (“Reverse Stock Split”) of its common stock, par value $0.0001 per share (“Common Stock”). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol “SXTP” and will begin trading on a split-ad","url":"https://finance.yahoo.com/news/60-degrees-pharmaceuticals-inc-announces-132600993.html"},{"category":"company","date":1722932880,"headline":"60 Degrees Pharmaceuticals announces 1-for-12 reverse stock split","id":129181945,"image":"","symbol":"SXTP","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3588178640"}]}